BioSpace News Archive

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its fiscal year 2022 third quarter ended March 31, 2022.

Quidel Corporation announced that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022.

LeMaitre Vascular, Inc. announced that it is participating in two upcoming investor conferences.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States, announced its annual financial results for the year ended December 31, 2021.

WellNow Allergy, an affiliate of leading urgent care provider WellNow Urgent Care, is now accepting patients in Liverpool, New York to provide allergy sufferers of all ages with convenient, on-demand access to allergy testing and immunotherapy.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced its financial and operating results for the first quarter of 2022.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, has filed its financial statements for the quarter ended March 31, 2022, in accordance with applicable Canadian securities laws.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022.

In preclinical animal studies, NVG-291 has demonstrated the potential to promote repair mechanisms in the nervous system, including plasticity, axonal regeneration, and remyelination.